

CURRICULUM VITAE

PAUL C. GORDON, MD

Address: The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906
Phone: Work: (401) 793-4102
Fax: (401) 793-4049
Email: pgordon@lifespan.org

EDUCATION

1982 BA Yale University
1986 MD Columbia University College of Physicians and Surgeons

POST-GRADUATE TRAINING

1986-1987 Internship in Internal Medicine, Beth Israel Hospital, Boston, MA
1987-1989 Residency in Internal Medicine, Beth Israel Hospital, Boston, MA
1989-1991 Clinical Fellowship in Cardiology, Beth Israel Hospital, Boston, MA
1991-1993 Fellowship in Interventional Cardiology, Beth Israel Hospital, Boston, MA

AWARDS AND HONORS

1982 Graduated Cum Laude and with Honors in Molecular Biophysics and Biochemistry
1986 Alpha Omega Alpha
1992 Physician-Investigator Award, American Heart Association, Massachusetts Affiliate
1995 Outstanding Teaching Faculty Award, Brown University Fellowship in Cardiovascular Disease
2004, 2009 Dean's Teaching Award, Brown University Alpert Medical School
2019 Dean's Excellence in Teaching Award, Clinical Faculty Advisory Committee Honoree, Brown University Alpert Medical School

LICENSURE AND CERTIFICATION

1987 Diplomate, National Board of Medical Examiners
1989 Commonwealth of Massachusetts Board of Registration in Medicine
1989 American Board of Internal Medicine Certificate
1991, 2001 American Board of Internal Medicine, Cardiovascular Disease, Certificate
1993 Rhode Island Board of Registration in Medicine
1999, 2009 American Board of Internal Medicine, Interventional Cardiology, Certificate

ACADEMIC APPOINTMENTS

1989-1992	Clinical Fellow in Medicine (Cardiology), Harvard Medical School and Beth Israel Hospital, Boston, MA
1992-1993	Instructor in Medicine (Cardiology), Harvard Medical School and Beth Israel Hospital, Boston, MA
1993-2012	Assistant Professor of Medicine (Clinical), Alpert Medical School at Brown University, Providence, RI
2003-2009	Program Director, The Miriam Hospital Interventional Cardiology Fellowship
2012-present	Associate Professor of Medicine (Clinical), Alpert Medical School of Brown University, Providence, RI

HOSPITAL APPOINTMENTS

1989-1993	Medical Staff, Emerson Hospital, Concord, MA
1993-present	The Miriam Hospital, Providence, RI, Active staff Medical Director, Cardiology Nurse Practitioner Service, The Miriam Hospital, 1999-2015 Director, Coronary Care Unit, The Miriam Hospital, 7/2001-11/2003 Director, Cardiac Catheterization Laboratory, The Miriam Hospital, 11/2003-9/2015
1993-2009	Roger Williams General Hospital, Providence, RI, Active staff
1998-2016	Charlton Memorial Hospital, Fall River, MA, Associate staff
2008-2015	Landmark Medical Center, Woonsocket, RI, Active staff

PEER REVIEWER

Journal of the American College of Cardiology, 1995-present
 American Journal of Cardiology, 1994-present
 Catheterization and Cardiovascular Interventions, 1993-present

HOSPITAL COMMITTEES

Miriam Hospital Medical Records Committee, 1994-present
 Miriam Hospital Emergency Room Committee, 1994-1999
 Blue Cross/Blue Shield of Rhode Island Cardiology Advisory Committee, 2000-2005
 Clinical Research Review Board, The Miriam Hospital, 2000-2004
 The Miriam Hospital Door-to-Balloon Committee, 2003-2010

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1986-present	Massachusetts Medical Society
1990-present	American College of Cardiology, Fellow
1993-present	Society for Cardiac Angiography and Interventions, Associate Fellow
1997-present	Rhode Island Medical Society

PUBLICATIONS

ORIGINAL REPORTS

1. Kuntz RE, Tosteson AN, Berman AD, Goldman L, **Gordon PC**, Leonard BM, McKay RG, Diver DJ, Safian RD. Predictors of event free survival after balloon aortic valvuloplasty. *N Engl J Med* 1991;325(1):17-23.
2. Kuntz RE, Tosteson AN, Maitland LA, **Gordon PC**, Leonard BM, McKay RG, Berman AB, Diver DJ, Safian RD. Immediate and long-term follow-up after repeat balloon aortic valvuloplasty. *Cathet Cardiovasc Diagn* 1992; 25(1):4-9.
3. **Gordon PC**, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilatation within coronary stents -- a quantitative angiographic assessment. *J Am Coll Cardiol* 1993;21:116-74.
4. **Gordon PC**, Kugelmass AJ, Cohen DJ, Breall JA, Friedrich SF, Carrozza JP, Diver DJ, Kuntz RE, Baim DS. Balloon Post-dilation Can Safely Improve the Results of Successful (but Sub-optimal) Directional Coronary Atherectomy. *Am J Cardiol* 1993;72:71E-79E.
5. **Gordon PC**, Kugelmass AJ, Breall JA, Leidig GA, Friedrich SF, Carrozza JP, Kuntz RK, Baim DS. Is 40-70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? *Am J Cardiol* 1994;74:26-32.
6. Nunez B, Miao L, Carrozza J, Ross J, Douglas P, **Gordon PC**, Katz SE, Kuntz R, Morgan JP. Cocaine-induced transmural myocardial infarction in a Yorkshire swine with normal coronary arteries: evidence for microvascular and/or epicardial coronary artery spasm. *Cardiovascular Pathology* 1994;3:93-7.
7. Fishman RF, Kuntz RE, Carrozza JP, Friedrich SP, **Gordon PC**, Senerchia CC, Baim DS. Acute and long-term results of coronary stents and atherectomy in women and the elderly. *Coronary Artery Dis* 1995; 6:159-68.
8. Nunez BD, Miao L, Kuntz RE, Ross JN, Gladstone S, Baim DS, **Gordon PC**, Morgan JP, Carrozza JP. Cardiogenic Shock induced by cocaine in swine with normal coronary arteries. *Cardiovascular Research* 1994;28:105-111.
9. Forman DE, **Gordon PC**, Parisi AF. Recent Advances in Cardiology. *HealthMed RI* 1996;79:165-174.
10. Lawrence ME, Burt DM, Shaftel PA, Saunders SE, Korr KS, **Gordon PC**. Intracoronary stenting without Coumadin or Intravascular Ultrasound. *Journal of Invasive Cardiology* 1996;8:428-32.

11. Leon MB, Baim DS, Popma JJ, **Gordon PC**, Cutlip DE, et al. A Randomized Trial Comparing Three Anti-thrombotic Drug Regimens Following Elective Coronary Stenting. *N Engl J Med* 1998 Dec 3;339(23):1665-71. PMID 9834303
12. Cutlip DE, Leon MB, Ho KKL, **Gordon PC**, et al. Acute and 9 month Clinical Outcomes after “Sub-optimal” Coronary Stenting – Results from the Stent Anti-thrombotic Regimen Study (STARS) Registry. *J Am Coll Cardiol* 1999 Sep;34(3):698-706. PMID 10483950
13. Sadaniantz A, **Gordon PC**. Multiple Ecchymotic Lesions on the Torso of a Patient with Unstable Angina. *Clin Cardiol* 2000;23(2):214-215. PMID 10761813
14. Pereira N, Parisi AF, Dec GW, Choo J, Hajjar R, **Gordon PC**. Myocardial Stunning in Hyperthyroidism. *Clin Cardiol* 2000;(4):298-300. PMID 10763082
15. **Gordon PC**. Primary Angioplasty for Acute Myocardial Infarction. *Health Med RI* 2001;84(2):44-50. PMID 11272659
16. Wu WC, **Gordon PC**, Invasive Management of Patients With ST elevation Myocardial Infarction with >12 Hour Delay Presentation: The question remains unanswered. *Chest* 2004;126(1):2-4. PMID 15249431
17. Stankovic G, Colombo A, Bersin R, Popma J, Sharma S, Cannon L, **Gordon P**, Nukta D, Braden G, Collins M. Comparison of Directional Coronary Atherectomy and Stenting versus Stenting Alone for the Treatment of De novo and Restenotic Coronary Narrowing. *Am J Cardiol* 2004;93:953-958.
18. Halkin A, Mehran R, Casey CW, **Gordon P**, Matthews R, Wilson BH, Leon M, Russell ME, Ellis SG, Stone GW. Impact of Renal Insufficiency on Restenosis and Adverse Clinical Events Following Paclitaxel-Eluting and Bare Metal Stent Implantation: Results from the TAXUS-IV Trial. *Am Heart J* 2005;150(6):1163-70. PMID 16338253
19. Rinaldi, MJ, Kirtane AJ, MD, Piana R, Caputo RP, **Gordon PC**, Lopez J, Dauerman HJ, Ryan TJ Jr, Kiernan FJ, Cutlip DE, Ho KL, Gibson CM, Murphy SA, Cohen DJ. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. *Am Heart J* 2008;155(4):654-60. PMID 18371472
20. Regnante R, OBell J, **Gordon P**. Renal Artery Stenosis: Clinical and Therapeutic Implications. *Health Med RI* 2008;91(10):315-19. PMID 19044107
21. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, **Gordon P**, White RM, Sudhir K, PhD, Cutlip DE, Petersen JL. Randomized Comparison of Everolimus-eluting and Paclitaxel-eluting Stents: Two-Year Clinical Follow-up from the SPIRIT III Trial. *Circulation* 2009Jan;37(1):93-8. PMID 19157353

22. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, **Gordon P**, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III Trial. *Circulation* 2009 Feb 10;119(5):680-6. PMID 19171853
23. **Gordon PC**, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. *Catheter Cardiovasc Interv* 2010 Feb 1;75(2):179-86. PMID 19877267
24. Wang Q, Pierson W, Sood, P, Bol C, Cannon L, **Gordon P**, Saucedo J, Sudhir K. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. *J Interv Cardiol* 2010 Feb;23(1):26-32. PMID 20040005
25. Applegate R, Hermiller J, Williams J, **Gordon P**, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, Stone G. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. *Catheter Cardiovasc Interv* 2010 Nov 1;76(5):644-51. PMID 20506356
26. Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, **Gordon P**, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW; SPIRIT II and III Investigators. Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT II (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. *JACC Cardiovasc Interv* 2010 Dec;3(12):1220-8. PMID 21232715
27. Kereiakes DJ, Sudhir K, Hermiller JB, **Gordon PC**, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [ECCSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. *JACC Cardiovasc Interv* 2010 Dec;3(12):1229-39. PMID 21232716
28. Delgado GA, Truesdell AG, Kirchner RM, Zuzek RW, Pomerantsev EV, **Gordon PC**, Regnante RA. An Angiographic and Intravascular Ultrasound Study of the Left Anterior

- Descending Coronary Artery in Takotsubo Cardiomyopathy. *Am J Cardiol* 2011 July 7. PMID 21741604
29. Delgado GA, Truesdell AG, Kirchner RM, Zuzek RW, Pomerantsev EV, **Gordon PC**, Regnante RA. Coronary Artery Disease and Takotsubo Cardiomyopathy: Culprit or Innocent Bystander? *J Heart Dis* 2011;8(1):22.
 30. Applegate RJ, Hermiller JB, **Gordon PC**, Yaqub M, Sood, P, Su X, Cao S, Sudhir K, Stone GW. Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. *Euro Intervention* 2011 Dec 30; 7(9):1030-42. PMID 22207228
 31. **Gordon PC**, Cohen DJ, Kleiman NS, Montgomery JA, Semder CA, Kennedy KF, Keyes MJ, Piana RN; on behalf of the EVENT Investigators. In-hospital and one year outcomes with drug-eluting versus bare-metal stents in large native coronary arteries a report from the evaluation of drug-eluting stents and ischemic events (EVENT) registry. *Catheter Cardiovasc Interv* 2012; Apr 18. Doi: 10.1002/ccd.24451. PMID 22511502
 32. Caputo RP, Goel A, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Waksman R, Tolerico P, Dhar G, **Gordon P**, Bach RG, Lopez JJ. Impact of Drug Eluting Stent Length on Outcomes of Percutaneous Coronary Intervention (from the EVENT Registry). *Am J Cardiol* 2012 May 3. PMID 22560770
 33. Hermiller JB, Sudhir K, Applegate RJ, Rizvi A, Wang J, **Gordon PC**, Yaqub M, Cao S, Ferguson JM, Smith RS Jr, Sood P, Stone GW. Impact of age on clinical outcomes after Everolimus-eluting and paclitaxel-eluting stent implantation: Pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. *Euro Intervention* 2012 May 15; 8(1):87-93. PMID 22580252
 34. Prabhu W, **Gordon PC**. Transcatheter Aortic Valve Replacement: A Review of Current Indications and Outcomes. *RI Med J* 2014 Feb 3;97(2):38-41. PMID 24494213
 35. Waksman R, Kirtane, AJ, Torguson R, Cohen DJ, Ryan T, Räber L, Applegate R, Waxman S, **Gordon P**, Kaneshige K, Leon MB; DESERT Investigators. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). *JACC Cardiovasc Interv* 2014 Oct;7(10):1093-102. PMID 25240540
 36. Solomon R, **Gordon P**, Manoukian SV, Abbott JD, Kereiakes DJ, Jeremias A, Kim M, Dauerman HL; on behalf the BOSS Trial Investigators. Randomized Trial of Bicarbonate or Saline Study for the Prevention of Contrast-Induced Nephropathy in Patients with CKD. *Clin J Am Soc Nephrol*. 2015 Sep 4; 10(9):1519-24. PMID 26185263
 37. Kolte D, Khera S, Sardar MR, Gheewala N, Gupta T, Chatterjee S, Goldsweig A, Aronow WS, Fonarow GC, Bhatt DL, Greenbaum AB, **Gordon PC**, Sharaf B, Abbott JD. Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States: Insights From the Nationwide Readmissions Database. *Circ Cardiovasc Interv*. 2017

Jan;10(1). pii: e004472. doi: 10.1161/CIRCINTERVENTIONS.116.004472. PMID: 28034845

38. Sardar MR, Khan ZA, Abraham A, Saeed W, Farhan M, Kolte D, Sharaf B, **Gordon P**, Sellke F, Sodha NR, Aronow HD, Ehsan A. Management Strategies and Possible Risk Factors for Ventricular Septal Defects After Transcatheter Aortic Valve Replacement: Case Series from a Single Center and Review of Literature. *Cardiovasc Revasc Med*. 2017 Sep;18(6):462-470. Epub 2017 Apr 8. pii: S1553-8389(17)30118-5. doi: 10.1016/j.carrev.2017.04.003. PMID 28455074
39. Khera S, Kolte D, Gupta T, Goldsweig A, Velagapudi P, Kalra A, Tang GHL, Aronow WS, Fonarow GC, Bhatt DL, Aronow HD, Kleiman NS, Reardon M, **Gordon PC**, Sharaf B, Abbott JD. Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. *JAMA Cardiol*. 2017 Jul 1;2(7):732-741. doi: 10.1001/jamacardio.2017.1630. PMID 28494061
40. Sardar MR, Goldsweig AM, Abbott JD, Sharaf BL, **Gordon PC**, Ehsan A, Aronow HD. Vascular Complications Associated with Transcatheter Aortic Valve Replacement. *Vasc Med* 2017 Jun;22(3):234-244. doi: 10.1177/1358863X17697832. PMID 28494713
41. Aala A, Sharif S, Parikh L, Gordon PC, Hu SL. High-Output Cardiac Failure and Coronary Steal With an Arteriovenous Fistula. *Am J Kidney Dis* 2018 Jun;71(6):896-903. doi: 10.1053/j.ajkd.2017.10.012. Epub 2017 Dec 23. PMID 29277506
42. Goldsweig AM, Kennedy KF, Kolte D, Abbott JD, **Gordon PC**, Sharaf BL, Sellke FW, Ehsan A, Sodha NR, Rutar F, Aronow HD. Predictors of patient radiation exposure during transcatheter aortic valve replacement. *Catheter Cardiovasc Interv* 2017 Dec 27. doi: 10.1002/ccd.27452. PMID 29280551
43. Velagapudi P, Kolte D, Ather K, Khera S, Gupta T, **Gordon PC**, Aronow HD, Kirtane AJ, Abbott JD. Temporal Trends and Factors Associated With Prolonged Length of Stay in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am J Cardiol* 2018 July 15;122(2):185-191. doi: 10.1016/j.amjcard.2018.03.365. Epub 2018 Apr 11. PMID 29751953
44. Louis DW, Kennedy K, Lima FV, Pancholy S, Abbott JD, **Gordon P**, Aronow HD. Association Between Maximal Activated Clotting Time and Major Bleeding Complications During Transradial and Transfemoral Percutaneous Coronary Intervention. *JACC Cardiovasc Interv* 2018 May 11. pii: S1936-8798(18)30428-X. doi: 10.1016/j.jcin.2018.01.257. PMID 29778734
45. Velagapudi P, Turagam M, Kolte D, Khera S, Hyder O, **Gordon P**, Aronow HD, Leopold J, Abbott JD. Intramyocardial autologous CD34+ cell therapy for refractory angina: A meta-analysis of randomized controlled trials. *Cardiovasc Revasc Med* 2018 June 5. PMID 29908826

46. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, Aronow HD, Elmariah S, Inglessis I, Palacios IF, Thourani VH, Sharaf BL, **Gordon PC**, Abbott JD. Outcomes Following Urgent/Emergent Transcatheter aortic Valve Replacement: Insights From the STS/ACC TVT Registry. *JACC Cardiovasc Interv* 2018 Jun 25;11(12):1175-1185 PMID 29929641
47. Imran HM, Baig M, Mujib M, Beale C, Gaw A, Stabile L, Shah NR, **Gordon PC**, Wu WC. Comparison of phase 2 cardiac rehabilitation outcomes between patients after transcatheter versus surgical aortic valve replacement. *Eur J Prev Cardiol*. 2018 Aug 8:2047487318792099. doi: 10.1177/2047487318792099. PMID 30086685
48. Bavishi C, Kolte D, **Gordon PC**, Abbott JD. Transcatheter aortic valve replacement in patients with severe aortic stenosis and heart failure. *Heart Fail Rev*. 2018 Nov;23(6):821-829. doi: 10.1007/s10741-018-9726-8. PMID 30094532
49. Waksman R, Rogers T, Torguson R, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, hanna N, Garrett R, Asch F, Weissman G, Ben-Dor I, Shults C, Bastian R, Craig PE, Garcia-Garcia HM, Kolm P, Zou Q, Satler LF, Corso PJ. Transcatheter Aortic Valve Replacement in Low-Risk Patients with Symptomatic Severe Aortic Stenosis. *J Am Coll Cardiol* 2018 Aug 9. pii: S0735-1097(18)36852-9. doi: 10.1016/j.jacc.2018.08.1033. PMID 30170075
50. Kolte D, Goldweig A, Kennedy KF, Abbott JD, **Gordon PC**, Sellke FW, Ehsan A, Sodha N, Sharaf BL, Aronow HD. Comparison of Incidence, Predictors, and Outcomes of Early Infective Endocarditis after Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in the United States. *Am J Cardiol* 2018 Sep 13. PMID 30292332
51. Apostolidou E, Aronow HD, Beale CE, Kolte D, Kennedy KF, Sellke FW, **Gordon PC**, Sharaf B, Ehsan A. Association Between Red Blood Cell Transfusion and Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement. *Ann Thorac Surg* 2018 Dec 12. PMID 30552884
52. Kolte D, Beale C, Aronow HD, Kennedy KF, Apostolidou E, Sellke FW, Sharaf BL, **Gordon PC**, Abbott JD, Ehsan A. Trends and outcomes of red blood cell transfusion in patients undergoing transcatheter aortic valve replacement in the United States. *J Thorac Cardiovasc Surg* 2019 Mar 28. PMID 31014667
53. Bavishi C, Chugh Y, Kimura T, Natsuaki M, Kaiser C, **Gordon P**, Aronow HD, Abbott JD. Biodegradable Polymer Drug-Eluting Stent versus Contemporary Durable Polymer Drug-Eluting Stents in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials. *Eur Heart J Qual Care Clin Outcomes*. 2019 Jun 22. pii: qcz031. doi: 10.1093/ehjqcc/qcz031. PMID 31228186
54. Ozaki Y, Garcia-Garcia HM, Rogers T, Torguson R, Craig PE, Hideo-Kajita A, **Gordon P**, Ehsan A, Parikh P, Bilfinger T, Butzel D, Buchanan S, Levitt R, Hahn C, Buchbinder M, Hanna N, Garrett R, Wilson SR, Goncalves JA, Ali S, Asch FM, Weissman G, Shults C, Ben-Dor I, Satler LF, Waksman R. Coronary Artery Disease Assess by Computed Tomography-Based Leaman Score in Patients with Low-Risk Transcatheter Aortic Valve

- Implantation. *Am J Cardiol* 2020 Jan 28. pii: S0002-9149(20)30063-1. doi: 10.1016/j.amjcard.2020.01.022. PMID: 32087995
55. Rogers T, Greenspun BC, Weissman G, Torguson R, Craig P, Shults C, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Buckbinder M, Asch F, Garcia-Garcia HM, Okubagzi P, Ben-Dor I, Satler LF, Waksman R. Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients. *JACC Cardiovasc Interv* 2020 Mar 23;13(6):726-735. PMID 32192693
 56. Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, **Gordon P**, Ehsan A, Parikh P, Bilfinger T, Levitt R, Hahn C, Roberts D, Ingram M, Hanna N, Comas G, Zhang C, Ben-Dor I, Satler LF, Garcia-Garcia HM, Shults C, Rogers T. Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Bicuspid Aortic Valve Stenosis. *JACC Cardiovasc Interv* 2020 May 11;13(9):1019-1027. PMID 32381181
 57. Lam MC, Naidu SS, Kolte D, Kennedy K, Feldman DN, Chu AF, Abbott JD, **Gordon P**, Aronow HD. Cardiac Implantable Electronic Device Placement Following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy in the US. *J Cardiovasc Electrophysiol*. 2020 Jul 16. doi: 10.1111/jce.14679. Online ahead of print. PMID32671899
 58. Sharma E, Beale C, Ehsan A, Sodha N, **Gordon P**, Apostolidou E. Plugging the Hole: Diagnosis and Management of Post-Myocardial Infarction Ventricular Septal Defect. *CASE (Phila)*. 2020 May 7;4(4):283-287. PMID 32875196
 59. Rogers T, Greenspun BC, Weissman G, Torguson R, Craig P, Shults C, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Buchbinder M, Asch F, Garcia-Garcia HM, Okugagzi P, Ben-Dor I, Satler LF, Waksman R. Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients. *JACC Cardiovasc Interv* 2020 Mar 23;13(6):726-735. PMID 32192693
 60. Khan JM, Rogers T, Weissman G, Torguson R, Rodriguez-Weiss FJ, Chezar-Azerrad C, Greenspun B, Gupta N, Medvedofsky D, Zhang C, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buichana S, Hanna N, Garrett R, Shults C, Buchbinder M, Garcia-Garcia HM, Kolm P, Satler LF, Hashim H, Ben-Dor I, Asch FM, Waksman R. Anatomical Characteristics associated with hypoattenuated leaflet thickening in low-risk patients undergoing transcatheter aortic valve replacement. *Cardiovasc Revasc Med* 2020 Sept 12:S1553-8389(20)30586-8. PMID 33129688
 61. Bavishi C, Trivedi V, Sellke FW, Gordon PC, Abbott JD. Myocardial Contractile Reserve and Mortality in Patients with Severe Aortic Stenosis with Impaired Left Ventricular Function Undergoing Transcatheter Aortic Valve Implantation. *Am J Cardiol* 2020 Nov 25:S0002-9149(20)31281-9. PMID 33248116

BOOK CHAPTERS

1. Regnante R, **Gordon P**. Altitude Sickness. In: *Ferri's Clinical Advisor 2010*, Ferri, FF [ed], Mosby Elsevier, Philadelphia, PA, pp. 41, 2009. ISBN 13:978-0-323-05609-0
2. Regnante R, **Gordon P**. Ventricular Septal Defect. In: *Ferri's Clinical Advisor 2010*, Ferri, FF [ed], Mosby Elsevier, Philadelphia, PA, pp. 1068-1069, 2009. ISBN 13:978-0-323-05609-0
3. Zuzek, RW, **Gordon P**. Trigger Finger. In: *Ferri's Clinical Advisor 2010*, Ferri, FF [ed], Mosby Elsevier, Philadelphia, PA, pp. 1022-1023, 2009. ISBN 13:978-0-323-05609-0

ABSTRACTS

1. **Gordon PC**, Weinberg E, Apstein CS, Lorell BH. Glycolytic Cytosolic ATP Modifies Lusitropic Reserve in Well-Oxygenated Hearts. *Circulation* 1991; 84(Supplement II):278.
2. Friedrich SF, **Gordon PC**, Leidig G, Berger CJ, Cohen DJ, Gibson CM, Miller MJ, Fishman RF, Carrozza JP, Piana RN, Kuntz RK. Clinical events following new interventional devices are determined by time-dependent hazards. *Circulation* 1992;86(Supplement I):785.
3. Hajjar RJ, **Gordon PC**, Gwathmey JK. Mechanism of action of Butanedione Monoxime on diastolic tone in ischemia. *Circulation* 1992;(Supplement I);827.
4. **Gordon PC**, Kuntz RE, Friedrich SP, Piana RN, Kugelmass AD, Gibson CM, Paik GY, Cohen DJ, Carrozza JP, Baim DS. Using clinical outcomes to assess new interventional devices. *J Am Coll Cardiol* 1993;21:35A.
5. Cohen DJ, Kuntz RE, Friedrich SP, **Gordon PC**, Breall JA, Ho KH, Weinstein MC, Baim DS. Cost-effectiveness of directional coronary atherectomy, stenting, and conventional angioplasty in single-vessel disease: a decision-analytic model. *J Am Coll Cardiol* 1993;21:227A.
6. **Gordon PC**, Mochizuki T, Weinberg EO, Gwathmey JK, Lorell BH. Butanedione Monoxime prevents diastolic contracture in prolonged no-flow ischemia without preserving ATP. *J Am Coll Cardiol* 1993;21:223A.
7. Piana RN, Kugelmass AD, Moscucci M, Cohen DJ, **Gordon PC**, Senerchia C, Kuntz RE. Angiographic and clinical outcome of endoluminal stenting for stenotic saphenous vein grafts -- single center experience. *Circulation* 1993 (abstract).
8. Moscucci M, Cohen DJ, Kugelmass AD, Piana RN, Senerchia CC, Friedrich SP, **Gordon PC**, Baim DS. Should small (non-Q wave) myocardial infarctions be considered "major" or "minor" complications after otherwise successful stenting or atherectomy? *Circulation* 1993 (abstract).

9. Cohen DJ, **Gordon PC**, Friedrich SP, Breall JA, Diver DJ, Weinstein MC, Baim DS. The cost-effectiveness of selective adjunctive balloon dilation after successful (but sub-optimal) directional coronary atherectomy: a decision-analytic model. *Circulation* 1993 (abstract).
10. Leon MB, Baim DS, **Gordon PC**, et al. Clinical and Angiographic Results from the Stent Anticoagulation Regimen Study (STARS). *Circulation* 1996; 94:I-685.
11. Deutsch E, **Gordon PC**, et al. Safety and Efficacy of Coronary Stenting after Recent Myocardial Infarction: Results from the Stent Anticoagulation Regimen Study (STARS). *Circulation* 1997; 96:I-2974.
12. Acute Results and One-Year Outcomes of the Stent Anti-thrombotic Regimen Study (STARS) Registry. *Circulation* 1997; 96:I-3315.
13. Late Clinical Results of the Stent Anticoagulation Regimen Study (STARS). *Circulation* 1997; 96:I-3317.
14. Aude YM, Pothula AR, Korr KS, Sharma M, **Gordon PC**: Combination Wiggle Wire, “Buddy” Wire Technique for Stent Delivery in Calcified, Tortuous Coronary Arteries. (Abstract) *Am J Cardiol* 88; No 5 (A), 42G, 2001.
15. Sadiq I, Weinsier S, Linsky R, Regnante R, Ahmed H, Lateef S, **Gordon P**. Predictors of Poor Outcomes in Patients With Takotsubo Cardiomyopathy. *European Heart Journal* 2008;29:S1, p.151.

PUBLISHED MULTICENTER TRIALS

1. The EPILOG Investigators. Platelet Glycoprotein IIb/IIIa Receptor Blockade and low-Dose heparin during Percutaneous Coronary Revascularization. *N Engl J Med* 336:1689-1696A, 1997. (local Principal investigator)
2. Hirulog Angioplasty Study Investigators, Treatment with bivalirudin (Hirulog) as compared to Heparin during coronary angioplasty for unstable or post-infarction angina. *N Engl J Med* 333:764-9, 1995. (local Principal investigator)
3. Nissen, SE, et al. (REVERSAL Investigators), Effect of Intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. *JAMA* 2004;291:1071-1080. (local Principal investigator)
4. Stone GW, Ellis S G, Cox D A, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, the **TAXUS-IV** Investigators. A Polymer-based, Paclitaxol-Eluting Stent in Patients with Coronary Artery Disease. *N Engl J Med* 2004; 350:221-231. (local Principal investigator)
5. The SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended

early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54. (local Principal investigator)

6. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. *Lancet* 2009 Oct 3;374(9696):1149-59. Epub 2009 Aug 28. PMID 19717185
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009 Sep 10;361(11):1045-57. Epub 2009 Aug 30. PMID: 19717846
8. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mockel M, Ochala A, Kellock A, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. *N Engl J Med* 2009 May 7;360(19):1946-59. PMID 19420364
9. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010;362(18):1663-74. PMID 20445180
10. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011 Mar 16;305(11):1097-105. PMID 21406646
11. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Gerald M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. *NEJM* 2011 Aug 25;365(8):699-708. PMID 21780946
12. **Gordon PC**, Cohen DJ, Kleiman NS, Montgomery JA, Semder CA, Kennedy KF, Keyes MJ, Piana RN; EVENT Investigators. In-hospital and one-year outcomes with drug-eluting versus bare metal stents in large native coronary arteries: a report from the Evaluation of

- Drug-Eluting Stents and Ischemic Events registry. *Catheter Cardiovasc Interv* 2013 Oct 1;82(4):E356-64. doi: 10.1002/ccd.24451 PMID 22511502
13. Lincoff, AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA* 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321 PMID 24682069
 14. Waksman R, Kirtane, AJ, Torguson R, Cohen DJ, Ryan T, Raber L, Applegate R, Waaxman S, **Gordon P**, Kaneshige K, Leon MB; DESERT Invesitgators JACC Cardiovasc Interv 2014 Sep 6 pii: S1936-8798(14)01161-3. doi: 10.1016/j.jcin.2014.04.017 PMID 25240540
 15. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *J Engl J Med* j2014 Dec 4;371(23):2155-66 doi: 10.1056/NEJMoa1409312 PMID 25399658
 16. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: The dual antiplatelet therapy randomized clinical trial. *JAMA* 2015 Mar 17;313(11):1113-21. PMID 25781440
 17. Ellis, SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. *N Engl J Med*. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12. PMID: 26457558
 18. Kolte D, Khera S, Sardar MR, Gheewala N, Gupta T, Chatterjee S, Goldsweig A, Aronow WS, Fonarow GC, Bhatt DL, Greenbaum AB, **Gordon PC**, Sharaf B, Abbott JD. Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States: Insights from the Nationwide Readmissions Database. *Circ Cardiovasc Interv*. 2017 Jan;10(1). pii: e004472. doi: 10.1161/CIRCINTERVENTIONS.116.004472. PMID 28034845
 19. Short-Term Effects of Tolvaptan in Patients with Acute Heart Failure and Volume Overload. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, **Gordon P**, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE; SECRET of CHF Investigators, Coordinators, and Committee Members. *J Am Coll Cardiol*. 2017 Mar 21;69(11):1409-1419. PMID: 28302292

20. Waksman R, Rogers T, Torguson R, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Asch F, Weissman G, Ben-Dor I, Shults C, Bastian R, Craig PE, Garcia-Garcia HM, Kolm P, Zou Q, Satler LF, Corso PJ. Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic Severe Aortic Stenosis. *J Am Coll Cardiol* 2018 Oct 30;72(18):2095-2105. PMID 30170075
21. Waksman R, Corso PJ, Torguson R, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Buchbinder M, Asch F, Weissman G, Ben-Dor I, Shults C, Bastian R, Craig PE, Ali S, Garcia-Garcia HM, Kolm P, Zou Q, Satler LF, Rogers T. Transcatheter Aortic Valve Replacement in Low-Risk Patients: One-Year Results from the LRT Trial. *JACC Cardiovasc Interv* 2019 Mar 8. pii: S1936-8798(19)30656-9. doi: 10.1016/j.jcin.2019.03.002. PMID 30860059
22. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstrale W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomized trial. *Lancet* 2019 Aug 30. pii: S0140-6736(19)31887-2. doi: 10.1016/S0140-6736(19)31887-2. PMID 31484629
23. Khan JM, Rogers T, Waksman R, Torguson R, Weissman G, Medvedofsky D, Craig PE, Zhang C, **Gordon P**, Ehsan A, Wilson SR, Goncalves J, Levitt R, Hahn C, Parikh P, Bilfinger T, Butzel D, Buchanan S, Hanna N, Garrett R, Shults C, Garcia-Garcia HM, Kolm P, Satler LF, Buchbinder M, Ben-Dor I, Asch FM. Hemodynamics and Subclinical Leaflet Thrombosis in Low-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Imaging*. 2019 Dec; 12(12):e009608. doi: 10.1161/CIRCIMAGING.119.009608. Epub 2019 Dec 12. PMID 31826675
24. Lima FV, Kolte D, Rofeberg V, Molino J, Zhang Z, Elmariah S, Aronow HD, Abbott JD, Ben Assa E, Khera S, **Gordon PC**, Inglessis I, Palacios IF. Thirty-day readmissions after transcatheter versus surgical mitral valve repair in high risk patients with mitral regurgitation: Analysis of the 2014-2015 nationwide readmissions databases. *Catheter Cardiovasc Interv* 2019 Dec 23. doi: 10.2002/ccd.28647 PMID 31868999
25. Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE Jr, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB; ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. *N Engl J Med* 2020 Apr 9;382(15):1408-1419. PMID 32227753
26. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamazy A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr,

Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020 Apr9;382(15):1395-1407. PMID 32227755

27. Pereira N, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, **Gordon P**, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 2020 Aug 25;324(8):761-771. PMID 32840598

INVITED PRESENTATIONS

1. Medical Grand Rounds, Roger Williams Medical Center, October 1995
2. Medical Grand Rounds, Roger Williams Medical Center, September 5, 2000
3. Medical Grand Rounds, Roger Williams Medical Center, June 24, 2003
4. Medical Grand Rounds, Fatima Hospital, May 6, 2004; Oct 3, 2006
5. Medical Grand Rounds, Roger Williams Medical Center, July 2005
6. Intervention 2004, Boston, MA, June 4, 2004, Faculty
7. Rhode Island Chapter of the American College of Cardiology, Update for Primary Care Physicians:
 - 9/2005: Carotid Artery Stenting
 - 9/27/2006: Plavix, Indications and Duration of Use in Coronary Artery Disease
 - 9/24/2008: Migraines and PFOs: Where are we Headed?
 - 9/23/2009: Emerging Trends in STEMI Care Mission Lifeline and Door to Balloon
 - 9/29/2010: Antiplatelet agents and Primary Coronary Intervention: What should the Internist know?
 - 11/12/14: Transcatheter Aortic Valve Replacement
8. Medical Grand Rounds, Roger Williams Medical Center, September 25, 2012
9. Cardiology Grand Rounds, Rhode Island Hospital, October 12, 2012
10. EMS Symposium, Lifespan Cardiovascular Institute, Case Panelist, Crown Plaza Hotel, Warwick, RI, February 25, 2019
11. 2019 Brown Heart Valve Symposium: Structural Heart Team Approach to Aortic & Mitral Valve Disease: Closing Gaps & Expanding Opportunities, Planning Committee, Lecturer, and Panelist, April 6, 2019

GRANTS

1. Site Principal Investigator, The Miriam Hospital, Biogen Protocol C92-304-P: A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of BG8967 with Heparin in Patients with Unstable Angina Undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA), 3/94-12/94. Sponsor – Biogen.
2. Site Principal Investigator, The Miriam Hospital, Protocol C0116T16 - A Phase III Randomized, Double-blind, Placebo-Controlled Trial Evaluating 30-day and 6-month Clinical Outcome following Percutaneous Coronary Intervention in Patients Treated with

c7E3 Fab Bolus plus 12-hour Infusion Given with Either Standard-Dose Weight-Adjusted or Low-Dose Weight-Adjusted Heparin, 7/95-present. Sponsor - Centocor.

3. Site Principal Investigator, Stent Anti-Thrombotic Regimen Study (STARS) Trial: A Randomized Study Evaluating the Outcome in Patients Treated with Uncoated Aspirin, Ticlid, or Coumadin Post Stent Placement, 11/95. Sponsor - Johnson & Johnson Interventional Systems.
4. Site Principal Investigator, CROWN stent Trial, Sponsor - Cordis, 1/97-6/03.
5. Site Principal Investigator, EXTRA Trial (BARD XT stent study), sponsor - BARD/USCI, 2/97.
6. Site Principal Investigator, VeGAS 2 Trial (Angiojet study), sponsor - Possis Medical, 2/97.
7. Site Principal Investigator, PAS Trial (PARAGON stent study), sponsor - Progressive Angioplasty systems, 2/97-06/00.
8. Site Principal Investigator, NIRVANA Trial (NIR stent study), sponsor - Medinol/Scimed, 2/97-4/05.
9. Site Principal Investigator, MINICROWN Stent Trial (MINICROWN stent study), sponsor - Cordis, Inc, 4/98.
10. Site Principal Investigator, CROSSFLEX-LC Stent Registry, sponsor – Cordis, 4/98-9/00.
11. Site Principal Investigator, PREDICT Stent Trial, sponsor – Medtronic/AVE, 1/99-7/00.
12. Site Principal Investigator, AMIGO Trial (Directional atherectomy with stent vs. stent only), sponsor – Guidant, 2/99-8/02.
13. Site Principal Investigator, POSTIT Study (Post dilatation clinical comparative study, randomized NIR vs. Tristar Stent), sponsor – Boston Scientific Scimed, Inc. 4/00-8/01.
14. Site Principal Investigator, Medtronic/AVE High Scaffolding Stent Registry, sponsor - Medtronic/AVE. 4/00 to 4/05.
15. Site Principal Investigator, COMPLY and COMMA Trials (complement inhibitor during acute MI), sponsor – Procter & Gamble Pharmaceuticals, 5/00-02.
16. Site Principal Investigator, REVERSAL Trial (atorvastatin vs. pravastatin effect on coronary artery plaque assessed by Intravascular Ultrasound), sponsor Parke-Davis and Pfizer, 5/00-3/03.
17. Site Principal Investigator, DISTINCT AC/TC Registry, sponsor: Biocompatibles. 9/00-5/02.

18. Site Co-Investigator, Left Main IVUS Registry, Prospective Cohort Study of Patients Who Undergo IVUS for an Inconclusive Left Main Coronary Angiogram, sponsor – Scripps Clinic. 9/00-10/05.
19. Site Principal Investigator, TENAX XR Stent Registry, sponsor: Biotronik.1/01-7/03.
20. Site Principal Investigator, PREVAIL Trial (anti-oxidant to prevent restenosis), sponsor - CHUGAI Pharmaceuticals. 1/02-10/03.
21. Site Principal Investigator, PRIDE Trial (distal protection device for SVG intervention), sponsor - Kensey-Nash. 1/02-10/04.
22. Site Principal Investigator, NIRFLEX™ US Study: NIRflex Premounted Stent in Native Coronary Arteries, sponsor - Medinol, Ltd. 1/02-4/05.
23. Site Principal Investigator, SYNERGY Trial (LMWH vs UFH for acute coronary syndromes with planned cath/PCI), sponsor - Aventis. 1/02-5/05.
24. Site Principal Investigator, AiMI Study – Randomized to ANgiojet vs. immediate definitive treatment only (Percusurge), sponsor - POSSIS Medical, Inc. 6/02-4/05.
25. Site Principal Investigator, PROTECT-TIMI 30, (UFH or LMWH with eptifibatide versus bivalirudin in high risk patients undergoing PCI). Sponsor - Millenium Pharmaceuticals, 1/03-1/04.
26. Site Principal Investigator, ASTEROID Trial (Effect of Rosuvastatin on IVUS derived coronary atheroma burden). Sponsor - Astra Zeneca. 1/03-3/06.
27. Site Principal Investigator, ICE-IT (safety and efficacy of the celsius control system to reduce infarct size as an adjunct to immediate PCI), Sponsor - Innercool, 8/03-1/05.
28. Site Principal Investigator, TAXUS V ISR: A Prospective, Randomized Trial Evaluating the Slow-Release Formulation TAXUS™ Paclitaxel-Eluting Coronary Stent in the Treatment of In-stent. Sponsor - Boston Scientific. 10/03-1/10.
29. Site Principal Investigator, PERISCOPE Trial (Pioglitazone vs. glimeperide on the rate of progression of coronary atherosclerosis as measured by IVUS), Sponsor - Takeda Pharmaceuticals, 12/03-5/05.
30. Site Principal Investigator, TAXUS IV (paclitaxel coated stent) Trial, sponsor - Boston Scientific. 12/03-1/10.
31. Site Principal Investigator, FINESSE (retavase and abciximab vs abciximab alone during PCI for acute MI). Sponsor - Johnson & Johnson, 1/04-4/05.

32. Site Principal Investigator, DEScover Registry (drug eluting stent registry), Sponsor - Cordis Corporation, 6/04-7/07.
33. Site Principal Investigator, EVENT Registry (drug eluting stent registry), Sponsor - Millennium Pharmaceuticals. 3/05-7/09.
34. Site Principal Investigator, TIMI 38 A Comparison of (CS-747) and Clopidogrel in Acute Coronary Syndrome subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38. Sponsor - Quintiles/Eli Lilly. 3/05-9/08.
35. Site Principal Investigator, HORIZONS trial (angiomas vs. GpIIb/IIIa inhibition and bare metal vs. drug eluting stents for acute MI and primary angioplasty), Sponsor - Cardiovascular Research Foundation. 6/05-1/10.
36. Site Principal Investigator, SPIRIT III trial (everolimus coated cobalt-chromium vision stent vs. paclitaxol coated Express stent for de novo coronary artery disease), Sponsor - Abbott Cardiovascular Systems, Inc. 6/05-3/12.
37. Site Principal Investigator, SPIRIT IV trial (Everolimus coated cobalt-chromium vision stent vs. paclitaxol coated Express stent for de novo coronary artery disease), Sponsor - Abbott Cardiovascular Systems, Inc. 8/06-6/13.
38. Site Principal Investigator, PFO Access Registry, sponsor - AGA Medical Corporation. 10/06-present.
39. Site Sub-Investigator, SAPPHIRE WW Registry, sponsor - Cordis Corporation. 1/07-present.
40. Site Principal Investigator, PLATO (A study of PLATelet inhibition and Patient Outcomes), Sponsor - AstraZeneca 7/07-5/09.
41. Site Co-Investigator, TAKOTSUBO REGISTRY, Assessment of coronary arteries by Intravascular Ultrasound in Patients with Takotsubo Cardiomyopathy, sponsor - The Miriam Hospital. 6/07-5/09.
42. Site Principal Investigator, TAXUS V de novo and In-stent restenosis trial, sponsor - Boston Scientific. 7/07-11/09.
43. Site Principal Investigator, ELITE, (Comparison Of The Cypher ELITE and The Cypher BX VELOCITY sirolimus-Eluting Stent Systems), Sponsor - Cordis. 2/08-present.
44. Site Principal Investigator, GRAVITAS (Gauging Responsiveness with A VerifyNow assay- Impact on Thrombosis And Safety) Sponsor - Accumetrics. 3/08-9/10.
45. Site Principal Investigator, TIMI 50, A Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist

for Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P=TIMI 50) (P04737), Sponsor: Schering-Plough Research Institute 7/08 – 2/12.

46. Site Principal Investigator, AWARE (Angiogenesis in Women with Angina Pectoris Who are Not Candidates for Revascularization) Sponsor: Cardium Therapeutics 8/08-6/09.
47. Site Principal Investigator, XIENCE V and XIENCE V DAPT (Everolimus Eluting Coronary Stent System (EECSS) USA post-Approval Study) Sponsor: Abbott Cardiovascular Systems Inc. 9/08-11/13.
48. Sub Investigator, DAL-OUTCOMES – A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS), Sponsor: Hoffman-Laroche, Inc. 1/09-11/12.
49. Site Principal Investigator, RESOLUTE (endeavor stent registry), sponsor: Medtronic. 5/09-present.
50. Sub Investigator, The SUPERB Study, Sponsor: IDEV Technologies, Inc. 9/09-9/11.
51. Site Principal Investigator, APPRAISE 2 (apixaban for prevention of ischemic events) Sponsor: Bristol-Meyers), 10/09-6/11.
52. Site Principal Investigator, DESERT (drug eluting stent registry of thrombosis), Sponsor: Medstar Research Institute, 12/09-3/12.
53. Site Principal Investigator, CYPRESS-DAPT (dual antiplatelet post stenting) Sponsor: Cordis, 12/08 to present.
54. Site Principal Investigator, HCRI-DAPT (dual antiplatelet post stenting) Sponsor: Harvard Clinical Research Institute, 12/09-present.
55. Site Principal Investigator. RI TAKOTSUBO REGISTRY, Assessment of coronary arteries by Intravascular Ultrasound in Patients with Takotsubo. Sponsor: The Miriam Hospital. 1/10-3/13.
56. Site Principal Investigator, ALECARDIO (cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular events in patients with recent acute coronary syndrome) Sponsor: Hoffman-Laroche, Inc. 4/10-present.
57. Site Principal Investigator, dal-Plaque (dalcetrapid for plaque regression, progression by IVUS evaluation, Sponsor: Hoffman-Laroche, Inc. 4/10-2011.
58. Site Principal Investigator, BOSS Trial. Sponsor: MD Scientific. 10/10-9/12.
59. Site Principal Investigator, EDUCATE STUDY. Sponsor: Medtronic. 10/10-present.

60. Sub Investigator, Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects with Acute Coronary Syndromes (VISTA-16) AN-CVD2233, Sponsor: Anthera Pharmaceuticals, Inc. 3/11-2012.
61. Site Principal Investigator, PEGASUS TIMI 54, Sponsor: Astra Zeneca. 5/11-present.
62. Site Principal Investigator, PRESERVE AMI Trial, Sponsor: Amorcyte. 12/4/12-present.
63. Site Principal Investigator, RENAL GUARD Trial, Sponsor: PLC Medical Systems, Inc. 12/20/12-present.
64. Site Principal Investigator, ABSORB TRIAL, Sponsor: Abbott Vascular. 5/13-present.
65. Site Principal Investigator, ISCHEMIA TRIAL, Sponsor: National Heart, Lung and Blood Institute. 8/12-present.
66. Site Principal Investigator, APPOSSITIONS TRIAL (STENTYS), Sponsor: Stentys, Inc. 5/13-present.
67. Site Principal Investigator, MGuard™ Prime Stent System Clinical Trial in Patients with Acute ST Elevation Myocardial Infarction, Sponsor: Inspire MD 1/14-6/15
68. Site Principal Investigator, Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI), Sponsor: Mayo Clinic 10/14-present
69. Site Principal Investigator, Siemens ACS Study, Sponsor: Siemens Healthcare Diagnostics, Inc. 2/15-present
70. Site Principal Investigator, A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 60 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus. (THEMIS-effect of Ticagrelor on Health outcomes in diabetes mellitus patients intervention study), Sponsor: AstraZeneca LP 5/14-present
71. Site Principal Investigator, BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial, Sponsor: Medinol Ltd. 5/15-present
72. Site Principal Investigator, BIOFLOW-V: BIOTRONIK – A Clinical Assessment of the SaFeTy and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions – V, Sponsor: Biotronik, Inc 6/15-present

73. Site Principal Investigator, Coronary InterventionS in High-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II), Sponosr: Thoractec Corporation 10/15-present
74. Site Principal Investigator, Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration, ALLSTAR), Sponsor: CapicorInc 9/15-present

UNIVERSITY TEACHING ROLES

1. Preceptor, Cardiac Pathophysiology – IMS 281 Brown University: 9/93, 9/94, 9/95, 9/96, 9/97, 9/98, 9/99.
2. Cardiology Service Attending, Roger Williams Medical Center 1/94, 1/95, 1/96
3. Cardiology Service Attending, The Miriam Hospital, 7/93 – present

HOSPITAL TEACHING ROLES

1. Cardiology Service Attending, The Miriam Hospital, 7/93 – present
Cardiology fellows and internal medicine residents and medical students on elective
4 hours/day X 5 days/week X 4 weeks/year = 80 hours/year
2. CCU/4West Teaching Attending, The Miriam Hospital, 8/94, 8/95, 6/96, 12/96, 10/97, 10/98, 3/00, 6/00, 7/01, 7/02, 1/03, 7/03, 1/04
3. Program Director, Interventional Cardiology Fellowship, The Miriam Hospital, Brown University, 11/2003 – 6/2009
4. Site Program Director, Interventional Cardiology Fellowship, Rhode Island and The Miriam Hospitals, Brown University, 7/2009 – present
General and interventional cardiology fellows on cath lab rotation
6 hours/day X 4 days/week X 46 weeks/year = 1104 hours/year

General and interventional cardiology fellows in outpatient clinic
3 hours/day X 2 days/week X 46 weeks/year = 276 hours/year